Literature DB >> 19268440

Histone deacetylase inhibitors that target tubulin.

Jörg Schemies1, Wolfgang Sippl, Manfred Jung.   

Abstract

Epigenetics is defined as heritable changes in gene expression that occur without changes in DNA sequence. Major mechanisms of epigenetics are post-translational histone modifications such as reversible acetylation. Histone deacetylases (HDACs) maintain the acetylation level of histones but also act on non-histone substrates that are involved in signal transduction or cellular transport processes. One important non-histone substrate is tubulin. The isotypes responsible for tubulin deacetylation are HDAC6 and the NAD(+)-dependent histone deacetylase (sirtuin) Sirt2. Here we review the action of those enzymes on tubulin and present an overview over existing inhibitors with a focus on their structural interaction with the targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268440     DOI: 10.1016/j.canlet.2009.01.040

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  The promise and failures of epigenetic therapies for cancer treatment.

Authors:  Pasano Bojang; Kenneth S Ramos
Journal:  Cancer Treat Rev       Date:  2013-07-05       Impact factor: 12.111

2.  TGF-β1 impairs mechanosensation of human osteoblasts via HDAC6-mediated shortening and distortion of primary cilia.

Authors:  Sabrina Ehnert; Vrinda Sreekumar; Romina H Aspera-Werz; Sahar O Sajadian; Elke Wintermeyer; Gunther H Sandmann; Christian Bahrs; Jan G Hengstler; Patricio Godoy; Andreas K Nussler
Journal:  J Mol Med (Berl)       Date:  2017-03-07       Impact factor: 4.599

Review 3.  The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.

Authors:  Paul A Marks
Journal:  Expert Opin Investig Drugs       Date:  2010-09       Impact factor: 6.206

4.  The molecular genetics of sirtuins: association with human longevity and age-related diseases.

Authors:  Letizia Polito; Patrick G Kehoe; Gianluigi Forloni; Diego Albani
Journal:  Int J Mol Epidemiol Genet       Date:  2010-06-20

5.  A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.

Authors:  U Lassen; L R Molife; M Sorensen; S-A Engelholm; L Vidal; R Sinha; R T Penson; P Buhl-Jensen; E Crowley; J Tjornelund; P Knoblauch; J S de Bono
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

6.  Influence of Hsp90 and HDAC inhibition and tubulin acetylation on perinuclear protein aggregation in human retinal pigment epithelial cells.

Authors:  Tuomas Ryhänen; Johanna Viiri; Juha M T Hyttinen; Hannu Uusitalo; Antero Salminen; Kai Kaarniranta
Journal:  J Biomed Biotechnol       Date:  2010-10-24

Review 7.  Histone deacetylase inhibitors: Potential in cancer therapy.

Authors:  P A Marks; W-S Xu
Journal:  J Cell Biochem       Date:  2009-07-01       Impact factor: 4.429

Review 8.  Histone deacetylases as targets for the treatment of human neurodegenerative diseases.

Authors:  Santosh R D'Mello
Journal:  Drug News Perspect       Date:  2009-11

Review 9.  Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.

Authors:  Sophia N Ononye; Michael van Heyst; Eric M Falcone; Amy C Anderson; Dennis L Wright
Journal:  Pharm Pat Anal       Date:  2012-05

10.  Synthesis and evaluation of substituted chroman-4-one and chromone derivatives as sirtuin 2-selective inhibitors.

Authors:  Maria Fridén-Saxin; Tina Seifert; Marie Rydén Landergren; Tiina Suuronen; Maija Lahtela-Kakkonen; Elina M Jarho; Kristina Luthman
Journal:  J Med Chem       Date:  2012-08-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.